| Literature DB >> 28229281 |
Christian Morath1, Anita Schmitt2, Florian Kälble3, Martin Zeier3, Michael Schmitt2, Flavius Sandra-Petrescu4,5, Gerhard Opelz4, Peter Terness4, Matthias Schaier3, Christian Kleist4,6.
Abstract
Refinement of immunosuppressive strategies has led to further improvement of kidney graft survival in recent years. Currently, the main limitations to long-term graft survival are life-threatening side effects of immunosuppression and chronic allograft injury, emphasizing the need for innovative immunosuppressive regimens that resolve this therapeutic dilemma. Several cell therapeutic approaches to immunosuppression and donor-specific unresponsiveness have been tested in early phase I and phase II clinical trials in kidney transplantation. The aim of this overview is to summarize current cell therapeutic approaches to immunosuppression in clinical kidney transplantation with a focus on myeloid suppressor cell therapy by mitomycin C-induced cells (MICs). MICs show great promise as a therapeutic agent to achieve the rapid and durable establishment of donor-unresponsiveness in living-donor kidney transplantation. Cell-based therapeutic approaches may eventually revolutionize immunosuppression in kidney transplantation in the near future.Entities:
Keywords: Immunosuppression; Mitomycin C-induced cells; Myeloid suppressor cells; Regulatory T cells; Tolerance; Transplantation
Mesh：
Substances：
Year: 2017 PMID： 28229281 DOI： 10.1007/s00467-017-3599-2
Source DB: PubMed Journal: Pediatr Nephrol ISSN： 0931-041X Impact factor: 3.714